MPO and EPO provide the basis for safe, broad-spectrum microbicidal
agents against serious and resistant infections.
Pre-clinical studies indicate that MPO and EPO are non-toxic, non-irritating,
non-genotoxic, and non-sensitizing in various formulations.
Multiple MPO formulations are in development for prevention of serious,
and often resistant, hospital-acquired infections.
Our unique MPO formulation holds the promise of a breakthrough in surgical
site infection prevention.
The MPO technology platform suggests the potential for use in preventing
infections in conventional and biological attack situations.
as a Partner
Applying highest quality science, research, and development to our partnerships
We leverage our proprietary know-how and technology platform through
product licensing and collaborations in areas of unmet clinical need.
The Exoxemis technology platform has the potential to change the paradigm
of infectious disease prevention and treatment by providing an alternative
to existing antibiotics and other anti-infectives.
We offer a comprehensive intellectual property portfolio in MPO and
EPO technologies protected by more than 20 patents worldwide.
Exoxemis’ scientific team members are active contributors to the
field’s body of knowledge in MPO technology.
An extensive literature on haloperoxidases supports the broad microbicidal
activity of MPO and EPO.